Abbott India cash flow

Latest FY26

Cash from operations: ₹1,319cr+30.4% on FY25
Free cash flow: ₹1,319cr+30.4% on FY25
Cash from financing: −₹1,066cr−₹925 cr in FY25
Cash from investing: −₹371cr₹182 cr in FY25

₹ crore except per share

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	30.0	71.8	71.2	70.0
	29.0	11.4	12.5	16.0
	−258	−258	−224	−142
	−1.2	—	—	—
	−65.2	−262	29.3	39.0
	15.7	−63.2	−1.7	−28.7
	31.8	40.5	96.0	−1.4
Cash from operating activities
	2,079	1,887	1,618	1,274
	1,859	1,459	1,617	1,234
	540	447	404	341
	1,319	1,012	1,213	893
Cash from investing activities
	28.6	0.5	0.2	0.5
	385	125	144	102
	−371	182	−416	−148
Cash from financing activities
	38.6	46.9	53.9	53.9
	0.1	—	—	—
	1,009	—	—	—
	−1,066	−925	−745	−639
	−118	269	52.1	107
	442	561	292	240
Reference items
	1,892	1,695	1,453	1,206
	27.3%	26.4%	24.8%	22.5%
	1,319	1,012	1,213	893
	—	—	₹570.73	₹420.42
	0.85×	0.72×	1.01×	0.94×
	540	447	404	341
	0.1	—	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

ABBOTINDIA₹26,275.00

Abbott India Ltd.

· Pharma & Health

₹ CrorePeersPFIZER GLAXO IPCALAB AJANTPHARM ANTHEM MEDANTA GLENMARK BIOCON

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	70.0	71.2	71.8	30.0
+ Finance Costs	16.0	12.5	11.4	29.0
+ Interest Income	-142.3	-224.0	-258.1	-258.2
+ Unrealised FX (Gain) / Loss	—	—	—	-1.2
Changes in Working Capital
+ Inventories	39.0	29.3	-262.5	-65.2
+ Trade Receivables — Current	-28.7	-1.7	-63.2	15.7
+ Trade Payables — Current	-1.4	96.0	40.5	31.8
Cash from Operating Activities
Profit Before Tax (per I/S)	1,273.8	1,617.8	1,887.0	2,079.3
Cash from Operations (pre-tax)	1,234.3	1,617.3	1,458.9	1,858.9
+ Income Taxes Paid	340.9	404.5	447.1	539.7
Cash from Operating Activities	893.4	1,212.8	1,011.8	1,319.2
Cash from Investing Activities
+ Disp of Fixed Assets	0.5	0.2	0.5	28.6
+ Interest Received — Investing	102.2	143.6	125.4	384.5
Cash from Investing Activities	-147.7	-416.0	182.2	-371.4
Cash from Financing Activities
+ Payment of Lease Liabilities	53.9	53.9	46.9	38.6
+ Interest Paid	—	—	—	0.1
+ Dividends Paid	—	—	—	1,009.3
Cash from Financing Activities	-638.7	-744.7	-925.2	-1,066.1
Net Changes in Cash	107.0	52.1	268.9	-118.3
Closing Cash	239.7	291.7	560.6	442.3
Reference Items
EBITDA	1,205.6	1,453.1	1,694.6	1,892.1
EBITDA Margin %	22.54	24.84	26.44	27.31
Free Cash Flow (CFO − Capex)	893.4	1,212.8	1,011.8	1,319.2
Free Cash Flow per Basic Share	420.42	570.73	—	—
Cash Flow to Net Income	0.94	1.01	0.72	0.85
Cash Paid for Taxes	340.9	404.5	447.1	539.7
Cash Paid for Interest	—	—	—	0.1

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.